Enhanced Radioiodine Uptake in a Patient With Poorly Differentiated Papillary Thyroid Cancer After Treatment With Rosiglitazone
Authors:
- Alan N. EliasAEAlan N. Elias
- Paul LizottePLPaul Lizotte
- 1 September 2006
- journal article
- case report
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 31 (9) , 517-519
Abstract
The effect of pretreatment with the peroxisome proliferator-activated receptor (PPAR) agonist, rosiglitazone, on radioiodine uptake and serum thyroglobulin levels in a patient with radioiodine-resistant papillary thyroid cancer is described. Treatment with rosiglitazone resulted in enhanced radioiodine uptake in areas of presumed metastatic disease in the neck that were previously only faintly seen, and serum thyroglobulin fell from a pretreatment level of 41 ng/mL to less than 2 ng/mL.Keywords
This publication has 25 references indexed in Scilit:
- PPAR Activation and Decreased Proliferation in Oral Carcinoma Cells With 4‐HPROtolaryngology–Head and Neck Surgery, 2005
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 2005
- Ligands for the peroxisome proliferator-activated receptor-γ have inhibitory effects on growth of human neuroblastoma cells in vitroToxicology, 2005
- Peroxisome proliferator-activated receptor-γ ligands for the treatment of breast cancerExpert Opinion on Investigational Drugs, 2005
- Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in cultureEndocrine-Related Cancer, 2005
- Treatment of Thyroid Cancer with Histone Deacetylase Inhibitors and Peroxisome Proliferator-Activated Receptor–γ AgonistsThyroid®, 2005
- Troglitazone, the Peroxisome Proliferator-Activated Receptor-γ Agonist, Induces Antiproliferation and Redifferentiation in Human Thyroid Cancer Cell LinesThyroid®, 2005
- Effect of peroxisome proliferator-activated receptor γ agonist, rosiglitazone, on dedifferentiated thyroid cancersNuclear Medicine Communications, 2004
- Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonistsThe Lancet Oncology, 2004
- PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDLCell, 1998